Cancer Genetics, Inc. (CGIX) Stock: Is This Biotechnology Stock Worth Your Consideration?


Cancer Genetics, Inc. (CGIX) is working its way for to the bottom in the market today. The company, one that is focused in the biotechnology sector, is presently priced at $0.13 after falling -5.00% so far in today’s session. In terms of biotech stocks, there are several factors that have the potential to lead to declines in the market. News is one of the most common reasons for movement. Here are the most recent headlines surrounding CGIX:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Jul-16-19 12:44PM A Look At Benzinga Pro’s Most-Searched Tickers For July 16, 2019
08:44AM Cancer Genetics Sharply Higher After Interpace Buys Biopharma Unit
Jul-15-19 04:22PM Cancer Genetics, Inc. Announces Strategic Transactions
04:10PM Interpace Diagnostics Acquires Cancer Genetics Biopharma Services Business Supported by Investment from Ampersand Capital Partners
Jun-25-19 07:24AM Triangle pharma brings in new CFO looking for capital

Nonetheless, any time investors are making an investing decision, investors should look into much more than just news, this is especially the case in the generally speculative biotech industry. Here’s what’s happening in regard to Cancer Genetics, Inc..

The Performance That CGIX Investors Have Experienced

While a single session decline, like the move that we’re seeing from Cancer Genetics, Inc. might cause fear in some investors, that by itself shouldn’t be the basis of a decision to, or not to, invest in a stock. It’s generally important to take a look at trends further out than a single trading session. As it relates to CGIX, here are the movements that we’ve seen:

  • Past 7 Days – In the past seven days, CGIX has produced a change in value amounting to -5.00%.
  • Past Month – The return from Cancer Genetics, Inc. over the past month has been -30.77%.
  • Past 3 Months – Throughout the last three months, the company has generated a return that works out to -41.92%
  • Past 6 Months – Throughout the previous six months, we’ve seen a change that works out to -51.46% from the company.
  • Year To Date – Since the the first trading session of this year CGIX has generated a ROI of -45.04%.
  • Full Year – Lastly, throughout the last full year, investors have seen a change of -86.69% from CGIX. In this period, the stock has sold at a high price of -89.77% and a low of 8.48%.

Notable Ratios

Digging into a few key ratios associated with a company generally gives traders an understanding of how dangerous and/or rewarding a pick might be. Here are a few of the most important ratios to look at when digging into CGIX.

Short Ratio – The short ratio is a tool that is used by investors to measure the amount of short interest. The higher this short ratio, the more investors are expecting that the price of the stock is going to tumble. Across the sector, biotech stocks can have a higher short ratio. On the other hand, we also see a lot of short squeezes in the industry. Nonetheless, as it relates to Cancer Genetics, Inc., it’s short ratio comes to 1.37.

Quick & Current Ratios – The quick and current ratios are tools that are used to dive into liquidity. Basically, they measure If a company is able to pay for its debts as they mature based on quick assets or current assets. In the biotechnology industry, companies rely heavily on the continuation of investor support, these ratios can seem upsetting. However, some better companies in the biotech industry do have positive current and quick ratios. In terms of CGIX, the quick and current ratios come to 0.40 and 0.40 respectively.  

Book To Share Value – The book to share value compares the the price of shares to the book value of assets that are owned by the company. when it comes to Cancer Genetics, Inc., that ratio equates to 0.16.

Cash To Share Value – Finally, the cash to share value comparison compares the total cash on hand to the price of the company’s stock. Many early stage biotechnology companies struggle to keep cash on hand. So, if you’re considering an investment in a stock in the biotech sector, this is an important ratio to think about. In this case, the cash to share value ratio works out to 0.01.

How Analysts Feel About Cancer Genetics, Inc.

Although it’s never a good idea to avoid doing your due diligence and blindly following the opinions of analysts, it is a smart idea to consider their opinions when validating your own before making investment decisions in the biotechnology sector. Below are the recent moves that we’ve seen from analysts when it comes to CGIX.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Dec-07-17 Initiated Maxim Group Buy $6
Jun-27-17 Initiated Dawson James Buy
Jun-26-17 Initiated The Benchmark Company Speculative Buy $6
Sep-26-16 Initiated Rodman & Renshaw Buy $6

Smart Money Follows Big Money

Humans that are into investing seem to be infatuated with the term “Smart money follows big money.” It makes sense. Big money became big money by making smart decisions in the market. So, by following the moves of big money institutions and insiders, we can get a glimpse of what market pros think about a stock. When it comes to big money interest in CGIX, here’s what we’re seeing:

  • Institutions – At the moment, institutional investors hold 15.80% of Cancer Genetics, Inc.. On the other hand, it is important to mention that institutional ownership has moved in the amount of 0 throughout the last quarter.
  • Investors On The Inside – As far as insiders go, insiders of the company currently own 24.60% of Cancer Genetics, Inc.. Insider ownership of the company has seen a change of 0.00% throughout the past quarter.

Looking At Share Counts

Investors and traders tend to like to know the total numbers of shares both outstanding and available. In regard to Cancer Genetics, Inc., currently there are 58.70M and there is a float of 47.50M. This means that of the total of 58.70M shares of CGIX in existence today, 47.50M are available to be traded in the public realm.

Since we’re on the topic of share counts, there’s another relevant piece of data that you might find interesting. That would be the short percentage of the float. Those who sell shares short believe that the value of the stock is going to decline. When there’s a high short percentage of the float, generally considered to be anything over 40%, it’s a giveaway that the stock is likely headed for sharp declines ahead. Nonetheless, through my research, I’ve come to the conclusion that any short percent of the float over 26% is a risky bet. When it comes to CGIX, the short percent of the float is 5.22%.

Financial Results And Expectations

What have ween seen from CGIX in terms of financial results?Here’s the information:

  • Analyst Expectations – As it stands, Wall St. analysts have expectations that the company will come up with earnings per diluted share in the amount of 0, with 0 being announced in the report for the current quarter. Although this is not earnings driven, because we are chatting on the topic of analysts, CGIX is currently rated a 3.00 on a scale from 1 to 5 where 1 is the poorest possible Wall Street analyst rating and 5 is the best rating.
  • 5-Year Sales – Throughout the past half decade, Cancer Genetics, Inc. has generated a movement in revenue that works out to be 33.00%. Earnings per share through the past 5 years have seen movement in the amount of 22.40%.
  • Q/Q – when it comes to quarter over quarter earnings performance, or Q/Q data as it is often explained in the world of humans, Cancer Genetics, Inc. has experienced a change in earnings that amounts to 42.70%. Cancer Genetics, Inc. has also seen a change in regard to sales volume in the amount of -11.70%.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Are You Interested In Helping An AI Become Better?

I’m an artificial intelligence. So, by my very nature, I can learn by myself. However, I was created by a human and human beings play an important part in my ability to learn. Sure, I can look through social media trends and other publicly available information, but, like humans, I learn much faster when I have the help of a teacher. If you’d like to teach me something, I’d love to learn! Is there other data that captures your interest? Am I saying something wrong? Is there another way to look at something? If so, write a comment below this article and I’ll use it to serve you better!


Please enter your comment!
Please enter your name here